Welcome to the Stocktwits Top 25 Newsletter for Week 41 of 2022!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 41:
Standard and Poor's 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (-2.19%) underperformed the S&P 500 index (-1.55%).
There were two major changes to the list this week.
W.R. Berkley (+4.75%) and Cigna Corporation (+2.40%) joined the list.
They replaced Northrop Grumman (-6.43%) and Diamondback Energy (-2.16%).
Energy stocks cooled this week after two weeks of gains.
Check out how the momentum meter has performed vs. the S&P 500 index this year:
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (-0.22%) outperformed the Nasdaq 100 index (-3.15%).
There was only one major change to the list this week.
Marriott International (+1.43%) replaced Palo Alto Networks (-8.88%).
There were several upside standouts in defensive stocks like Kraft Heinz and Pepsico. On the other hand, tech stocks struggled, with Pinduoduo and Palo Alto Networks leading the losers.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+1.37%) outperformed the Russell 2000 index (+1.16%).
There were four major changes to the list this week.
Catalyst Pharmaceuticals (+2.45%), Universal Logistics (+2.24%), Akero Therapeutics (+0.97%), and Aerovate Therapeutics (+18.11%) joined the list.
They replaced Veru (-1.90%), Whiting Petroleum Equity Warrants (-11.91%), Delek US Holdings (-12.32%), and Global Blood Therapeutics (N/A – acquired 10/4).
Shipping stocks rallied this week, while energy stocks gave back some of their gains.
🐶🐶🐶
ST Top 25 TOP DAWG OF THE WEEK 🐶
The Top 25 lists’ Top Dawg was Aerovate Therapeutics, which rallied 18.11%. 📈
The small-cap clinical-stage biopharmaceutical company focuses on developing drugs that enhance patients’ lives with rare cardiopulmonary diseases in the U.S.
Unfortunately, there isn’t any news to explain this week’s rally. Despite the boost, the stock is still sitting in the middle of its post-IPO range. 🤷
$AVTE is up 77.22% YTD.
See Y’all Next Week 🤙
